Company

About

aceRNA Technology

aceRNA Technology

Kyoto, Japan

aceRNA Technologies Co., Ltd. is a biotech startup established in 2018 based on RNA design technology developed in synthetic RNA biology research by Prof. Hirohide Saito at Kyoto University. We are developing "smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner. By that, we are committed to develop new therapeutic approach, such as in vivo cell programming.

PURMX

PURMX

1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima 734-8553, Japan

Creation of optimal nucleic acid medicine for disease treatment with proprietary technology PURMX's solution is a drug discovery seed of small RNA nucleic acid drugs that fine-tune many target genes and deliver unprecedented therapeutic effects. PURMX already possesses a large amount of functional RNA screening data, which is being further expanded. The first stage of innovative nucleic acid medicine seeds is MIRX002. MIRX002 is a nucleic acid medicine for malignant pleural mesothelioma. We have completed non-clinical trials and are conducting investigator-initiated clinical trials at Hiroshima University Hospital starting in 2021.

Reborna Biosciences

Reborna Biosciences

Fujisawa, Japan

Reborna Biosciences is a Japan based startup company developing RNA-targeting small molecule drugs for rare genetic diseases. Our proprietary screening method discovers orally available small molecules by reproducing the natural three-dimensional structure of RNA that exists in human body. Therefore, it can be expected to identify drug candidates having a higher extrapolation to clinical practice than the conventional screening method using artificially fragmented RNA (a form that does not exist in the body). We are convinced that this unique technology will contribute to the development of therapeutic drugs with higher efficacy and fewer side effects.